Corporate Information: Aethlon Medical, Inc.

Company Description

Aethlon Medical, Inc. - A Technical Summary of the Hemopurifier™ Biodefense and Newly Emerging Pathogens
Aethlon Medical is pioneering the development of immunotherapeutic devices able to mimic the immune response of clearing viruses and viral toxins from circulation. The Company's lead product, the Hemopurifier(TM), converges the established principals of hemodialysis and affinity chromatography with the discovery of compounds that effectively adhere to the surface of a multiple envelope viruses. The Hemopurifier(TM)is targeted to treat acute and chronic infectious diseases, including drug and vaccine resistant Biological Weapons, the Human Immunodeficiency Virus (HIV) and the Hepatitis-C Virus (HCV). The Company has an experienced management team, which receives support and guidance from globally recognized science and regulatory advisors representing the infectious disease, biowarfare and dialysis industries.

New Weapons Against Infectious Disease

Aethlon Medical is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body. Aethlon has published compelling human blood studies of the HemopurifierTM to treat HIV/AIDS and Hepatitis-C (HCV), and most recently, has announced that it is developing pathogen filtration devices to treat infectious agents used in biological warfare and terrorism. The Hemopurifier is a proprietary platform technology that converges the established scientific principles of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. 

Published HIV/AIDS & HCV Data

Aethlon's science publications document that on average, the HIV-Hemopurifier removes 55% of HIV from human blood in three hours, and in excess of 85% in twelve hours. The HIV-Hemopurifier also cleared 90% of the toxic protein gp-120 in one hour. GP-120 is known for depleting healthy immune cells, which is the hallmark of AIDS. The HCV-Hemopurifier removed 58% of the Hepatitis-C virus from infected blood in two hours. The HIV & HCV Hemopurifiers are designed to enhance and prolong current drug therapies, and treat infected patients who inevitably become resistant to available drug regimens.

Countermeasures Against Bioterrorism

Aethlon recently announced that it is developing treatments to combat infectious agents used in biological warfare and terrorism. These Hemopurifiers are designed for rapid deployment by American armed forces as wearable post-exposure treatments on the battlefield, as well as a dialysis based treatments for civilian populations. Aethlon is focusing its biodefense strategy on "Category A" agents that are considered by the Centers for Disease Control (CDC) to be the worst bioterror threats. These agents include the viruses that cause Smallpox, hemorrhagic fevers such as Ebola and Marburg, the Anthrax bacteria, and Botulinum toxin. In addition to these pathogens, Aethlon is uniquely suited to treat unknown new toxins or hybrid pathogen strains. The most frightening forms of these infectious diseases are genetically engineered biological weapons designed to kill large population masses. 

Aethlon's biowarfare treatments are based on the same proprietary HemopurifierTM filtration technology that is utilized in advancing the Company's HIV/AIDS, and Hepatitis-C treatments. The regulatory path for Aethlon's biowarfare treatments will be pursuant to a recent rule implemented by the U.S. Food and Drug Administration for medical countermeasures to weapons of mass destruction. Under this rule, in situations where it is deemed unethical to conduct efficacy studies in humans, a treatment can be reviewed for approval on the basis of efficacy in the most relevant animal species and safety data in humans. On March 4, 2004, Aethlon announced a cooperative agreement with the National Center for Biodefense (NCBD) at George Mason University. Under the agreement, Aethlon and the NCBD will collaborate to develop pathogen and toxin filtration devices designed to protect the lives of U.S. Military personnel exposed to infectious agents as a result of biological warfare.

Regulatory Affairs

Dr. Kenneth Michael serves as a Clinical and Regulatory Affairs Advisor to Aethlon Medical. Dr. Michael is the former Vice President of Regulatory Affairs and Quality Assurance at Siemens Medical Systems, and was the founder, past President, and Chairman of The Regulatory Affairs Professionals Society (RAPS), an international professional society representing over 8000 healthcare Regulatory Affairs professionals. 

Contact:
James A. Joyce
Chairman, CEO
Phone: 619.368.2000
Email: jj@aethlonmedical.com 

This summary may contain forward-looking statements concerning the potential and prospects of the Company's Hemopurifier treatment technology. Any statement describing a goal, expectation, intention or belief of the Company is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including the failure to successfully complete clinical trials, the Company's future capital needs, the Company's ability to obtain additional funding and required regulatory approvals, the ability of the Company to protect its intellectual property rights, the development of competitive products by other companies and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.